Overview

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Status:
Not yet recruiting
Trial end date:
2028-01-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals